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ABSTRACT
The aim of this study was to investigate the effectiveness of a synthetic polyethy lenglycol
(PEG) sealant to prevent lymphocele formation after kidney transplantation. The exam-
ined group consisted of 719 recipients including 294 female and 425 male who were
immunosuppressed with a calcineurin inhibitor, plus basiliximab since 1999, and with
mycophenolate mofetil in addition since 2000. We retrospectively analyzed the incidence
of lymphoceles among 545 recipients operated between November 1999 and November
2007 (group I), 93 recipients at standard risk for lymphocele transplanted between
December 2007 and December 2009 (group II) in whom we performed only routine
ligation of the lymphatic vessels during preparation of the graft, and 31 patients also
transplanted between December 2007 and December 2009 who were at higher risk for
lymphocele (group III) and underwent an off-label application of the PEG sealant. There
was no significant difference in patient demographic features among the groups. In total,
21 group I, patients (3.5%) developed symptoms of a lymphocele that required 1
corrective procedures, whereas only 1 group II patient (1.07%) developed a lymphocele
and no group III patient evidenced a symptomatic lymphocele. No adverse events were
observed among group III patients after PEG sealant application. although the preliminary
results are interesting, a prospective randomized study is required to assess the cost-
effectiveness of PEG sealant to prevent lymphocele formation.
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mLymphocele is one of the most common complicationsafter kidney transplantation with, incidences up to
26%1,2 and the potential for graft loss. Although several
herapies are currently available to treat clinically signifi-
ant lymphoceles, the only prevention until now his con-
isted of prceise ligation of lymphatic vessels during the
reparation of the transplant. The aim of the present study
as to perform a retrospective analysis of lymphocele
ncidence among a consecutive series of 719 recipients,
ome of whom were treated with a polyethyleneglycol
PEG) sealant to prevent this complication.
PATIENTS AND METHODS
Among 2,925 kidney transplants performed over 40 years we
examined a consecutive series of 719 patients, including 294 female
and 425 male, who were transplanted between November 1999 and
December 2009 and all immunosuppressed using protocols with a
calcineurin inhibitor, plus basiliximab since 1999, and in addition
mycophenolate mofetil since 2000.
We retrospectively analyzed the incidence of a lymphocele
among all recipients operated between November 1999 and No-
vember 2007 (group I; n  595), when only minimal dissection of
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1072the iliac vessels and preasi ligation of lymphatic vessels was
performed using no resorbable sutures before divisitn during
preparation of the graft. The 124 patients transplanted in the more
recent period between December 2007 and December 2009 were
divided into 2 groups: group II patients, (n  93) underwent only
Foutine ligation of the lymphatic vessels during preparation of the
graft, and group III patients, (n 31) who were suspected to be at
greater risk for lymphocele, underwent a liberal “off-label” appli-
cation of a PEG sealant.
This entirely synthetic sealant is formed by 2 PEG, that when
mixed adhere to proteins by covalent chemical bonds,3 forming a
exible clear clot. The PEG sealant swells up to 4 times its original
olume within 24 hours of application, but it does not restrict the
ovement of surrounding tissues and was originally used by us to
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SYNTHETIC SEALANT TO PREVENT CYMPHOCELE 1073control “medical” hemorrhage in patients with severe coagulation
deficiencies. We noted by chance that the clot also stops lymph flow
from severed lymphatic vessels, acting effectively as mechanical
compression, thus eliminating dead space and increasing adher-
ence of tissue plans. Therefore, we decided to use it to prevent
lymphorrhea, spraying it onto the surface of the iliac vessels and
the graft hilum in 31 patients, who were suspected to be at risk for
lymphocele: presence of large lymphatics, pretransplantation uro-
logical/gynecologic, operations, retransplantations, graft decapsu-
lation, and or congenital malformations of the recipient urinary
tract. We used a spray device with a separate pump or the standard
applicator. Only a thin uniform layer of sealant was applied to
avoid complication of mechanical compression or adverse effects of
entry of the sealant into a vessel lumen.
Among group I, the mean recipient age was 40.9  15.8 years
(range, 2–71), with 39.8% female and 60.2% male, mean dialysis
period 55.3  48.6 month (range  1–348), modality 27.7%
peritoneal dialysis (PD), 72.3% hemodialysis (HD), and 4.4%
preemptive cases; graft sources 14.5% living donors (LD) and
deceased donors (DD) 85.5%, 12.3% retransplantation and 29.9%
pre-transplantation urologic operations. The mean donor age was
44.4  17.8 years (range, 0–77).
Among group II, the mean recipient age was 40.0  19.4 years
(range 1–73), with 46.2% female and 53.8% male, mean dialysis
period 43.5  29.6 months (range 2–178), modality 30.3% PD
69.7% HD and, 9.3% retransplantations, 2 patients who had
previously received liver transplantations 2.1% pretransplantation
urologic operations. The mean donor age was 45.1  20.6 years
(range, 1–75).
Among group III, the mean recipients age was 41.8  17.9 years
(range, 4–68), with 45.2% female amd 54.8% male mean dialysis
period 71.0  46.2 months (range, 9–204), modality 12.9% PD vs
87.1% HD and 0% preemptive graft source 3.2% LD and 96.8%
DD, and 61.3% retransplantation. All of these patients had under-
gone urologic operations in the pretransplantation period, which
was considered to be a risk factor for the development of a
lymphocele. The mean donor age was 44.1  19.0 years (range,
1–70).
There was no significant difference in patient demographic
features and original diseases among the groups. All patients were
monitored by sonography for the occurrence of lymphocele in the
posttransplantation period for 8 months. We only considered for
correction, symptomatic disorders such as increased serum creati-
nine levels as a result of urinary tract obstruction or ipsilateral leg
swelling, abdominal/perinephric discomfort, and/or large (150
mL) collections. For initial treatment we need needle aspiration for
differential diagnosis with percutaneous drainage and sclerother-
apy. Subsequently, if the lymphocele persisted 1 week, we
performed a laparoscopic intraperitoneal marsupialization when-
ever the collection was anterior to the vessels. When the lympho-
cele was multiloculated or inferomedial, we perfomed an open
internal marsupialization. In cases of infection, we preferred an
external marsupialization. The endpoints were the incidence oflymphocele in the 2 groups primarily and patient and graft survival
secondarily by using the Kaplan-Meier method. Regarding the
onset, an early lymphocele was considered to be one that occurred
30 posttransplantation days versus late 30 days.
RESULTS
No patient or graft was lost as consequence of the correc-
tive interventions. None of the patients developed adverse
events after the administration of the PEG sealant. In
group I, 21 patients (3.5%) displayed lymphoceles, includ-
ing 11 in the early postoperative period at a mean of 24.6 
4.3 days (range, 8–30), and 10 in the late period between 35
and 750 postoperative days (mean, 122.3  22.3). These
patients underwent 26 surgical procedures as well as 21
percutaneous drainages with sclerotherapy; 19 internal
marsupializations (videolaparoscopic or open), 2 external
drainages, and 2 operations for recurrence. A lower abbeit
not significant (P  .5) incidence of lymphocele was ob-
served among group II, where only 1 patient (1.07%), who
had no risk factor for lymphocele, developed a symptomatic
lesion at 28 days that was successfully addressed by a
reoperation. No lymphocele was observed among group III.
Patient survival at 1 and 2 years, was not significantly
different among the 3 groups, namely 99.1% and 99.1%,
respectively, in group I and 98.3% and 97.8%, for group II
and group III. Graft survivals not censored for death, were
94.1% and 93.9%, respectively, for the group I, 93.5% and
93.5% for group Il, and 90.3% and 90.3% for group III. The
log-rank test between graft survivals of group II and group
III were not significantly different (P  .54).
DISCUSSION
Although preliminary results with intraoperative adminis-
tration of PEG sealant in patients at high risk for lympho-
cele are interesting, a prospective randomized study is
required to assess the real cost-effectiveness of this product
for routine use, owing to its relatively high cost.
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